Antipsychotics and neutropoenia: An update

<p>Background and objectives: Drugs are a common reason for neutropoenia. The aim of this paper is to review the scientific evidence available in regard to cases of neutropoenia associated with the use of antipsychotics.</p><p>Methods: A bibliographic review of the last five years...

Full description

Saved in:
Bibliographic Details
Main Authors: Luis Menéndez Rodríguez (Author), Jose Angel Méndez Sánchez (Author), Martin Menéndez Rodríguez (Author), Antonio Iglesias Pérez (Author), Santiago Fernández Blas (Author), Maria Del Carmen Hernández Sánchez (Author)
Format: Book
Published: Annals of Psychiatry and Treatment - Peertechz Publications, 2021-03-29.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 peertech__10_17352_apt_000027
042 |a dc 
100 1 0 |a Luis Menéndez Rodríguez  |e author 
700 1 0 |a  Jose Angel Méndez Sánchez  |e author 
700 1 0 |a  Martin Menéndez Rodríguez  |e author 
700 1 0 |a  Antonio Iglesias Pérez  |e author 
700 1 0 |a  Santiago Fernández Blas  |e author 
700 1 0 |a Maria Del Carmen Hernández Sánchez  |e author 
245 0 0 |a Antipsychotics and neutropoenia: An update 
260 |b Annals of Psychiatry and Treatment - Peertechz Publications,   |c 2021-03-29. 
520 |a <p>Background and objectives: Drugs are a common reason for neutropoenia. The aim of this paper is to review the scientific evidence available in regard to cases of neutropoenia associated with the use of antipsychotics.</p><p>Methods: A bibliographic review of the last five years collected in Pubmed, Uptodate, specifications of antipsychotics and the most important Clinical Practice Guidelines, was performed.</p><p>Results: The frequency of neutropoenia associated with the use of antipsychotics and agranulocytosis is 3% and 1%, respectively. Neutropoenia is most common during the first three months of treatment. Some risk factors are prior neutropoenia, age, sex, comorbidities or genetic susceptibility. Mortality is extremely rare. Most cases of neutropoenia patients are free of symptoms and they are detected in the laboratory. However, when neutropoenia is severe, the patient can even begin to present sepsis. It is recommended undertaking healthcare education for carers and patients on alarm data. The use of clozapine has a protocol for specific management and monitoring, which reduced the incidence of agranulocytosis and mortality. The incidence of neutropoenia is lower with second and third generation antipsychotics compared to clozapine.</p><p>Conclusion: The incidence of neutropoenia with antipsychotics is low. However, it is a potentially severe adverse effect. Blood work up in series needs to be performed during treatment with antipsychotics. It is possible that drugs with major antipsychotic potential such as clozapine are under used because of difficulties with their management and monitoring.</p> 
540 |a Copyright © Luis Menéndez Rodríguez et al. 
546 |a en 
655 7 |a Review Article  |2 local 
856 4 1 |u https://doi.org/10.17352/apt.000027  |z Connect to this object online.